AXON — Axon Enterprise, Inc.

As of 2026-08-27, sentiment is clearly bullish: Q2 2026 revenue grew 35.3% YoY to $904.4M, management raised FY2026 revenue guidance to 32–34%, future contracted bookings hit a record $15.1B (up 41% YoY), and Wall Street keeps a Buy consensus with 17 buys, 4 holds, and 0 sells. The consensus price target of $660.83 and more recent average of $703.29 sit above the current $611.20 price.

Revenue growth is genuinely accelerating, not a blip: Q2 2026 revenue of $904.4M was up 35.3% YoY, following 33.8% YoY in Q1 2026 and 38.5% YoY in Q4 2025, and the company has now posted 10 straight quarters of 30%+ revenue growth. Gross margin is stable around 59–61%. The weak spot is GAAP profitability: operating margin was only 5.2% in Q2 2026 and 2.6% TTM, down from the roughly 10–14% range in 2023, due to heavy R&D ($208.7M in Q2 alone), SG&A, and stock compensation. GAAP net income is heavily distorted by tax and other one-off items—Q1 2026 showed $169.3M net income on only $29.2M operating income—so non-GAAP metrics matter more; Q2 non-GAAP EPS was $1.88 with a 26.8% adjusted EBITDA margin. Cash flow is the clearest laggard: TTM free cash flow is only about $133M, with negative FCF in both Q1 and Q2 of 2026.

Expensive. As of 2026-08-27, the trailing P/E is 246x, the forward P/E is roughly 79x FY2026 consensus EPS of $7.70, and the TTM price-to-sales ratio is 15.3x versus its own five-year average of 14.5x. The PEG ratio is unhelpful here because trailing GAAP EPS is distorted by tax items. The stock is priced for continued 30%+ growth and meaningful margin expansion, leaving little room for disappointment.

At $611.20, the stock is pricing in about 79x FY2026 earnings estimates, so the market is effectively underwriting another strong year of software growth and operating leverage. The record $15.1B backlog and 39% ARR growth support that, but there is no margin of safety: if FY2027 guidance or Q3 software growth disappoints, a 79x forward multiple can compress fast. Conversely, if non-GAAP margins keep expanding, earnings can catch up to the price over time, making the multiple look less extreme.

As of 2026-08-27, the technical picture is positive but extended: RSI is 54.7 (neutral, not overbought), price is 1.7% above the 20-day SMA (~$601), 10.4% above the 50-day SMA (~$554), and 20.7% above the 200-day SMA (~$506). The trend is intact, but buying 20% above the 200-day offers poor risk/reward versus waiting for a pullback toward $554 or at least a retest of the 20-day around $601.

• Persistent geopolitical tensions and defense modernization are driving demand for counter-drone systems and public-safety technology.
• Municipal, state, and federal law-enforcement budgets remain structurally supportive, though a recession-driven budget crunch could slow contract awards.
• Higher-for-longer interest rates pressure long-duration, high-beta growth stocks; AXON's ~1.4 beta amplifies rate-driven selloffs.
• Tariff and supply-chain costs affect hardware gross margins; Q2 2026 benefited from tariff refunds, a tailwind that may not repeat.
• AI regulation and police-tech privacy scrutiny could create headline and political risk, especially in international markets.

• Q3 2026 earnings, expected in early November 2026, with focus on whether software/ARR growth stays above 35% and guidance is raised again.
• Dedrone counter-drone adoption and international police department contract wins as the next growth engine.
• Axon Assistant and Vision AI monetization, driving software attach, ARR growth, and the 126% net revenue retention rate.
• Conversion of the record $15.1B future contracted bookings into revenue and the potential for additional large federal/defense contracts.

• Multiple compression risk: ~79x forward EPS is unforgiving if growth decelerates below 30% or the FY2027 margin outlook disappoints.
• Weak cash conversion: TTM FCF of roughly $133M is far below reported net income, and negative H1 2026 FCF points to working-capital and stock-compensation drag.
• Thin GAAP operating margins (2.6% TTM) mean heavy R&D and SG&A spending may not translate to operating leverage as quickly as investors hope.
• Concentration in government customers exposes Axon to procurement cycles, budget politics, and police-tech controversies.
• Insider selling of over $120M across the trailing 12 months could signal that long-term holders see limited near-term upside.

Axon is a best-in-class public-safety technology compounder with durable 30%-plus revenue growth, record backlog, and strong software retention—the fundamental story is real. But at $611.20 and roughly 79x forward earnings, the stock is already pricing in a lot of the good news. I would not short it, but I also would not chase it here; a pullback toward the $550s or a Q3 print that confirms margin and cash-flow improvement would make the entry much more attractive.

Calculated by applying a justified forward P/E of roughly 84x to FY2026 consensus EPS of $7.70 (84.4 × $7.70 ≈ $650). The multiple reflects Axon's strong growth, 39% ARR growth, 126% net revenue retention, and 26.8% adjusted EBITDA margin, but is tempered by thin GAAP margins, lumpy free cash flow, and a Rich-vs-own-history valuation; it lands below the consensus average target of $660.83 and recent average of $703.29.